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Objectives: To determine the prevalence and factors associated with the use of opioids
among patients with chronic non-cancer pain (CNCP).
Methods: A systematic review and meta-analysis. Comprehensive literature searches in
Medline-PubMed, Embase and SCOPUS databases. Original studies published between
2009 and 2019 with a cross-sectional design were included. The quality of the studies was
assessed with Critical Appraisal Checklist for Studies Reporting Prevalence Data from the
Joanna Briggs Institute. Protocol registered in the International Prospective Register of
Systematic Reviews with reference number: CRD42019137990.
Results: Out of the 1,310 potential studies found, 25 studies fulfilled the inclusion criteria.
Most of the studies were of high quality. High levels of heterogeneity were found in the
studies included. In the general population, the prevalence of long-term opioid use was
2.3% (95% CI: 1.5–3.6%), the prevalence of short-term opioid use was 8.1% (95% CI:
5.6–11.6%), and among people with chronic low back pain it was 5.8% (95% CI:
0.5–45.5%). The prevalence of opioid use among patients from the health records or
medical surveys was 41% (95% CI: 23.3–61.3%). Finally, in patients with musculoskeletal
pain, the prevalence was 20.5% (95% CI: 12.9–30.9%) and in patients with fibromyalgia,
24.5% (95% CI: 22.9–26.2%). A higher prevalence of opioid use was observed among
men, younger people, patients receiving prescriptions of different types of drugs, smokers
and patients without insurance or with noncommercial insurance. In addition, non-white
and Asian patients were less likely to receive opioids than non-Hispanic white patients.
Conclusions: The prevalence of opioid use among patients with CNCP was higher in
subjects with short or occasional use compared to those with long-term use. Men,
younger people, more chronic pain conditions, and patients without insurance or with
noncommercial insurance were most related to opioid use. However, non-white and
Asian patients, and those treated by a physician trained in complementary medicine were
less likely to use opioids.
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INTRODUCTION
Chronic pain (CP) is a major public health concern (Vos et al.,
2012) that is associated with disability, distress, and a decrease in
the quality of life of affected individuals (de Sola et al., 2016). The
prevalence of moderate to severe CP in the general adult
population ranges from 2 to 55% in different countries
(Azevedo et al., 2012; Mohamed Zaki and Hairi, 2015; Mills
et al., 2019), with an estimated global annual cost of over US$245
billion (GSK, 2017).
The physiopathology of CP has been recognized to involve
complex interactions between physical, psychological, and social
factors, and that its appropriate management requires a
multidisciplinary approach (Broekmans et al., 2010). However,
pharmacological therapy remains a mainstay for treating these
patients (Timmerman et al., 2016), opioids being one class of
pharmacotherapies that is frequently prescribed to modulate pain
(Parsells Kelly et al., 2008).
Opioid therapy has attracted growing interest recently related
to the increased use observed in CP patients (Cheung et al., 2014;
Alam and Juurlink, 2015;Webster et al., 2017). This situation is of
particular concern in patients with chronic non-cancer pain
(CNCP), where the evidence of opioid therapy benefits may be
less robust than that observed in patients with acute or cancer
pain (Von Korff et al., 2011; Scholten, 2013; Campbell et al.,
2015). The duration of opioid therapy is also important with
regard to the benefits for patients, since the prescription of
opioids may be appropriate for short-term pain relief, but
long-term opioid therapy (LTOT) cannot be associated with
improvements in pain or function (Karmali et al., 2020).
Furthermore, despite the lack of information on the efficacy of
opioids (Warner, 2012), the introduction of high-dose and
extended-release oral tablet formulations of opioids has been
shown to increase the total prescriptions among CNCP patients,
especially in the last decade (Von Korff et al., 2011; Alam and
Juurlink, 2015; Severino et al., 2018). In some European countries,
such as Spain, the use of opioids increased by 83.59% from 2008 to
2015 (De Sola et al., 2020). Additionally, in 2016, more than one-
third of adults were prescribed opioids in the United States (Walker,
2018), making it an important social problem (Sehgal et al., 2012;
Salazar et al., 2019). The differences in opioid prescribing patterns
have been related to age, gender, ethnicity, pain diagnosis, number
of total medications, payment type, physician specialty, and patient
relationship with provider (Rasu and Knell, 2018).
Determining the prevalence of their use and factors underlying
its prevalence can advance our understanding of current
treatment practice and its impact on public health. Thus, it is
necessary to collect updated information about the prevalence of
the therapeutic use of opioids for CNCP in different countries,
and summarize the information published. Additionally, it is
necessary to take into account the length of the treatment and
factors associated with it to produce international estimates.
To this end, we carried out a systematic review of the literature
to know the prevalence of the therapeutic use of opioids in
patients with CNCP and, as a second aim, to analyze the
factors associated with their use. We also performed a meta-
analysis of the prevalence of the therapeutic use of opioids to
summarize the information obtained.
Following the PICOS method, the research question of this
systematic review is: What are the prevalence and factors
associated with the use of opioids among patients with CNCP?
METHODS
Protocol and Registration
The present systematic review and meta-analysis was conducted
following the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis statement (Shamseer et al., 2015)
(Supplementary Material SI). The study protocol was
registered in the International Prospective Register of
Systematic Reviews with reference number: CRD42019137990.
Design of the Study
Systematic review and meta-analysis.
Search Strategy
A systematic search strategy was built according to PICOS
method and performed in the Medline-PubMed, Embase and
SCOPUS databases. The terms/keywords of interest were
“opioid,” “analgesic,” and “pain.” The terms were combined
with the tag for searching in title, abstract and keywords.
Search terms and search strategies were adapted to each
database (Supplementary Material SII, TI). In light of the
differences in the prevalence of opioid use in the last decade,
the recent original studies, i.e., published in English or Spanish
from January 2009 to December 2019 with a cross-sectional
design were included.
Once the search strategies for all the databases were executed,
we imported all the references found into the Covidence online
tool (Veritas Health Innovation Ltd., 2019). The process of
duplicate removal, screening, data extraction and risk of bias
analysis were performed by this web-based systematic review tool.
Eligibility Criteria
The population of interest was people (all ages) with chronic non-
malignant pain. Those studies related to CNCP located in specific
body regions (e.g. musculoskeletal CP) were also included. Thus,
the term “CNCP” was not included in the search strategy in order
not to limit the searches to studies presenting only data from
general CNCP. The criteria to define CNCP and the specific body
regions that each study focuses on are specified in Table 2.
In this review, we exclusively focused on opioid treatment as
an intervention for pain. The use of opioid treatment can be
defined as self-reported use, self-reported prescription
medications and prescription, or dispensed drugs retrieved
from electronic health records (see Table 2). A study was
selected when its main outcome was the prevalence of the use
of opioids in CNCP, as long as these data were shown within the
study or it was possible to calculate prevalence from it. Studies
analyzing the factors associated with the use of opioids were also
included.
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Studies reporting the use of opioids in patients with acute,
post-operative, palliative, or cancer pain were excluded. Studies
focusing on the opinions or attitudes of physicians about opioid
prescription or on the disorders derived from their
consumption were also excluded (Supplementary Material
SII, T2).
Study Selection
Two authors (MD and HS) independently screened the title and
abstract of all of studies. Shortlisted studies were then analyzed in
depth according to the inclusion criteria, and their reference lists
were also revised to identify studies that could be included in the
review.
Risk of Bias Assessment
The quality of the studies was assessed following the Critical
Appraisal Checklist for Studies Reporting Prevalence Data from
the Joanna Briggs Institute (Munn et al., 2015). This checklist
consists of nine items regarding sample frame, appropriate
recruitment, adequate sample size, appropriate description of
the subjects and setting, data analysis, method used, the reliability
of condition measures, appropriateness of the statistical analysis
and response rate (Table 1). Each item was assessed as “yes,”
“no,” “unclear” or “not applicable.” For standardization, “yes”
was considered to imply a low risk of bias, and “no” and “unclear”
a high risk of bias. Since there is not a standard classification for
the “Critical Appraisal Checklist for Studies Reporting Prevalence
Data from the Joanna Briggs Institute,” some systematic reviews
were consulted to guide our classification (Porto De Toledo et al.,
2017; Bett et al., 2019; Peterson et al., 2019). A study was
considered to have a low risk of bias (i.e., high-quality study)
when it accumulated at least seven items answered as “yes” and a
moderate risk of bias when the study reached 4–6 “yes.” Any
disagreements regarding the suitability of a study were resolved
by a third author (AS).
Data Extraction
Information was extracted about the primary aim of the study, the
characteristics of the population, the sample source, sample size,
method for data retrieval, response rate, the definition of CNCP
considered in each study, the prevalence of CNCP in the
population studied, the prevalence of opioid use, the method
for obtaining this prevalence data, and the factors associated with
opioid use (Table 2).
Statistical Analysis
A descriptive analysis of the characteristics of all the studies
included in the systematic review was carried out. A meta-
analysis was performed if two or more studies reported the
same characteristics in the information provided and the same
measure of effect. In order to manage heterogeneity, the studies
were first grouped according to the following aspects: the source
of the sample (the general population or health registries/medical
surveys); the duration of opioid treatment [long-term, commonly
defined as more 3 months or short-term (Karmali et al., 2020)]
and the type of pain (Table 3).
Six subgroups were established. Group A included studies
carried out in the general population including people with
CNCP, where the duration of the use of opioids was long-
term or persistent (Fredheim et al., 2014; Birke et al., 2016).
Group B included studies in the general population including
people with CNCP, but in which the duration of the use of opioids
was short-term (Kurita et al., 2012; Azevedo et al., 2013; Fredheim
et al., 2014; Birke et al., 2016; Miller et al., 2017). Group C
included studies in the general population which analyze people
with chronic low back pain (CLBP) who had been using opioids
(Gouveia et al., 2017; Shmagel et al., 2018). Group D consisted of
studies that included patients with CNCP from health registries
who had been using opioids (Henderson et al., 2013; Romanelli
et al., 2017; Lin et al., 2019). Group E included studies with
patients from medical surveys with musculoskeletal conditions
[comprising musculoskeletal pain, osteoarthritis and CLBP,
following The International Classification of Diseases
(Ministerio De Sanidad Consumo y Bienestar Social, 2020)]
and who had been using opioids at the moment of the study
(Knoop et al., 2017; Sites et al., 2018; Rodondi et al., 2019; Van
Den Driest et al., 2019; Callhoff et al., 2020). Finally, group F
TABLE 1 | Risk of bias assessment. Checklist for studies reporting prevalence
data from the Joanna Briggs Institute (N  25).
Author name,
year
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9
Ahn, 2016 Yes Yes Unclear Yes Yes Yes Yes Yes NA
Azevedo, 2013 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Birke, 2016 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Callhof, 2019 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Fain, 2017 Yes Yes Yes Yes Yes Yes Yes Yes NA
Fredheim, 2014 Yes Yes Yes Yes Yes Yes Yes Yes No
Gouveia, 2017 Yes Yes Yes Yes Yes Yes Yes Yes No
Häuser, 2012 Yes Yes Unclear Yes Yes Yes No Yes No
Henderson, 2013 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Kingsbury, 2014 Yes Yes Yes Yes Yes Yes Yes Yes No
Knoop, 2017 Yes Yes Yes Yes Yes Yes Yes Yes No
Kurita, 2012 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Larochelle, 2015 Yes Yes Yes Yes Yes Yes Yes Yes NA
Lin, 2019 Yes Yes Yes Yes Yes Yes Yes Yes NA
Marschall, 2015 Yes Yes Yes Yes Yes Yes Yes Yes NA
Miller, 2017 Yes Yes Yes Yes Yes No Yes Yes Yes
Miller, 2019 Yes Yes Yes Yes Yes Yes Yes Yes NA
Rodondi, 2019 Yes No Yes Yes Yes No Yes Yes Yes
Romanelli, 2017 Yes Yes Yes Yes Yes No Yes Yes NA
Scala, 2018 Yes Yes Unclear Yes Yes No Yes Yes No
Shmagel, 2018 Yes Unclear Yes Yes Yes Yes Yes Yes Unclear
Sites, 2018 Yes Yes Yes Yes Yes Yes Yes Yes NA
Van den Driest,
2019
Yes Yes Yes Yes Yes Yes Yes Yes Yes
Vincent, 2015 Yes Yes Yes Yes Yes Yes Yes Yes No
Wand, 2016 No No Yes Yes Yes Yes Yes Yes Unclear
Q1, Was the sample frame appropriate? Q2, Participants were appropriately recruited?
Q3, Sample size was adequate? Q4, Study subjects and setting were described? Q5,
Was the data analysis conducted with sufficient coverage of the identified sample? Q6,
Were valid methods used for the identification of the condition? Q7, Was the condition
measured in a standard, reliable way for all participants? Q8, Was there appropriate
statistical analysis? Q9,Was the response rate adequate or managed appropriately? NA,
Not applicable.
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TABLE 2 | Characteristics of the studies included in the systematic review.
First author,
Year
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A General Population Surveys General Chronic pain Long-term
use
Q  12.44; df  1; p < 0.001
I2  91.96
There is heterogeneity
Birke, 2016 63 3,501 1.8 (1.4–2.3) —
Fredheim, 2014 417 14,477 2.9 (2.6–3.2)
Summary Prevalence 2.3 (1.5–3.6)
B General Population Surveys General Chronic pain Short-term use Q  275.47; df  4; p < 0.001
I2  98.55
There is heterogeneity
Miller, 2017 393 3,146 12.5 (11.4–13.7) Egger’s test: p  0.1119
Begg’s test: p  0.2207Birke, 2016 137 3,501 3.9 (3.3–4.6)
Fredheim, 2014 1787 14,477 12.3 (11.8–12.9)
Azevedo, 2013 76 1786 4.3 (3.4–5.3)
Kurita, 2012 407 3,305 12.3 (11.2–13.5)
Summary Prevalence 8.1 (5.6–11.6)
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There is heterogeneity
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Gouveia, 2017 24 1,487 1.6 (1.1–2.4)
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Begg’s test: p  0.6015Romanelli, 2017 69,935 120,481 58.0 (57.8–58.3)
Henderson, 2013 356 1,088 32.7 (30.0–35.6)
Summary Prevalence 41.0 (23.3–61.3)
E Health records or Medical Surveys Musculoskeletal
Conditions
Unspecified Q  509.24; df  4; p < 0.001
There is heterogeneity
Callhof, 2019 531 3,564 14.9 (13.8–16.1) Egger’s test: p  0.2391
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Knoop, 2017 79 656 12.0 (9.8–14.8)
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There is heterogeneity
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included studies of fibromyalgia patients from medical surveys
who had been using opioids (Häuser et al., 2012; Vincent et al.,
2015) (Table 3).
Studies carried out in a population of a specific age (Fain
et al., 2017), those that could not be compared with any other
study, such as those focused on a specific type of pain
(Kingsbury et al., 2014; Marschall et al., 2015), those from
specific sample sources (Wand et al., 2016; Scala et al., 2018;
Miller et al., 2019), and those focused on visits rather than the
patients (with the potential overlapping of the records of the
patients) (Larochelle et al., 2015; Ahn et al., 2016) were excluded from
the meta-analysis.
The measurement of effect for each study and the summary
measure (prevalence of opioid use, defined as the number of
subjects taking opioids divided by the number of individuals
with CNCP) were calculated with 95% CI. Also, the logit
transformation with 95% CI and with standard error and
variance were obtained to stabilize the variance (Barendregt
et al., 2013). Studies were weighted according to the prevalence
of the effect size and the inverse of the study variance.
The heterogeneity between the studies was determined by the
DerSimonian and Laird method with Cochran’s Q statistic. As
heterogeneity was observed in all the study subgroups, random
effects models were performed, which considers the variability
of the results due to the differences between the studies. The
proportion of total variability due to the heterogeneity of the
studies was estimated using the I2 value. The results of the meta-
analysis are presented in forest plots. To assess the potential
publication bias in groups with three or more studies, a funnel
plot, along with Begg’s rank correlation and Egger’s weighted
regression methods, were used. Two-tailed p < 0.05 was
considered indicative of a statistically significant publication bias.
Finally, a sensitivity analysis was carried out in groups with
three or more studies to determine the influence of each of the
studies on the overall estimate of the effect, and therefore the
robustness or stability of the final measurement obtained,
through influence graphs.
The data were analyzed using Comprehensive Meta-Analysis
Software Version 3.0 (Biostat, Englewood, NJ, USA).
RESULTS
The search identified 1,310 potential studies. After the selection
process (Figure 1), 22 suitable studies were identified. Three
more studies obtained by the additional search strategies (citation
search) were added.
Risk of Bias Assessment
Twenty-two of the 25 studies that remained fulfilled at least seven
items of the checklist, indicating a low risk of bias. The response
rate (Q9) was not reported by seven studies and the use of valid
methods for the identification of the condition (Q6) was not
reported by 4 (Table 1).
Study Characteristics
Out of these 25 studies, nine had been performed in the general
population (Kurita et al., 2012; Azevedo et al., 2013; Fredheim
et al., 2014; Kingsbury et al., 2014; Ahn et al., 2016; Birke et al.,
2016; Gouveia et al., 2017; Miller et al., 2017; Shmagel et al.,
2018), and sixteen in patients with CNCP from medical surveys
or medical records (Häuser et al., 2012; Henderson et al., 2013;
Larochelle et al., 2015; Marschall et al., 2015; Vincent et al.,
2015; Wand et al., 2016; Fain et al., 2017; Knoop et al., 2017;
Romanelli et al., 2017; Scala et al., 2018; Sites et al., 2018; Lin
et al., 2019; Miller et al., 2019; Rodondi et al., 2019; Van Den
Driest et al., 2019; Callhoff et al., 2020) (Table 2). The data were
gathered from thirteen countries. Most of the studies (n  15)
were restricted to adult populations (18 years or older), whereas
two study also included adolescents (≥16 years) (Kurita et al.,
2012; Birke et al., 2016), three included children (all ages)
(Henderson et al., 2013; Ahn et al., 2016; Miller et al., 2017),
and one only included people over 65 (Fain et al., 2017). In four
studies, the age was not specified. Thirteen studies were
performed in patients suffering from a chronic painful
process of specific cause (e.g., musculoskeletal pain) (Häuser
et al., 2012; Kingsbury et al., 2014; Larochelle et al., 2015;
Vincent et al., 2015; Ahn et al., 2016; Wand et al., 2016;
Gouveia et al., 2017; Knoop et al., 2017; Shmagel et al., 2018;
Sites et al., 2018; Rodondi et al., 2019; Van Den Driest et al.,
2019; Callhoff et al., 2020). The reported participation rates in
the studies ranged from 37% (Rodondi et al., 2019) to 84.8%
(Miller et al., 2017), but in some instances, the information
FIGURE 1 | Flowchart.
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given by the authors was missing or unclear (Table 2). CP was
defined as pain lasting at least 6 months in five of the studies
included (Kurita et al., 2012; Fredheim et al., 2014; Birke et al.,
2016; Miller et al., 2017; Scala et al., 2018), while in the rest, it
was considered as pain lasting longer than 3 months. The
prevalence of CNCP in the studies carried out in the general
population ranged from 6.8% (Romanelli et al., 2017) to 35.7%
(Azevedo et al., 2013) (Table 2).
FIGURE 2 | Results and ForestPlots of the meta-analyses for opioid use in different types of pain from diferent sources.
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Prevalence of Opioid use
Out of the nine studies set in the general population, two
distinguished between short-term or occasional opioid users
and long-term or persistent opioid users (Fredheim et al.,
2014; Birke et al., 2016). The prevalence was higher in those in
which the use was short or occasional (3.9%–12.3% vs.
1.8%–2.9%) (Kurita et al., 2012; Fredheim et al., 2014; Birke
et al., 2016). Three studies (out of nine in the general
population) focused on CLBP, and the prevalence ranged
from 1.6% (Gouveia et al., 2017) to 18.8% (Shmagel et al.,
2018). Another study retrieving data from five countries
focused on osteoarthritis, the total prevalence of opioid
being use 16.7% (Kingsbury et al., 2014).
In the studies analyzing the population frommedical registries
or medical surveys, the use of opioids was variable: 32.7% in
patients treated in general practices (Henderson et al., 2013),
28.4% among commercially insured patients (Miller et al.,
2019) and 64.4% in patients receiving care in a pain center
(Scala et al., 2018). In the studies in patients suffering a specific
pain condition, the use of opioids ranged from 13.1 to 20.8% in
the case of musculoskeletal pain (Larochelle et al., 2015; Sites
et al., 2018), from 12% (Knoop et al., 2017) to 22% in
osteoarthritis (Callhoff et al., 2020) and from 8.4% (Häuser
et al., 2012) to 22.4% in fibromyalgia (Vincent et al., 2015). The
highest prevalence of opioid use was 81.2% in a study
performed in a nursing home with people ≥65 years (Fain
et al., 2017) (Table 2).
Factors Associated with the use of Opioids
Seven of the studies included in the review analyzed the
factors associated with the use of opioids, reporting a
greater use of these drugs in men (Fredheim et al., 2014;
Romanelli et al., 2017), in young people (Fredheim et al., 2014;
Larochelle et al., 2015; Romanelli et al., 2017), in patients
receiving prescriptions for different kinds of drugs (Fredheim
et al., 2014), in people with a lower educational level (Shmagel
et al., 2018), in smokers (Rodondi et al., 2019), and in patients
without insurance or with noncommercial insurance,
especially Medicaid and Medicare, vs. those with private
insurance (Larochelle et al., 2015; Romanelli et al., 2017;
Lin et al., 2019) (Table 2).
The use of opioids was also related to the physician. Patients
followed by a physician had higher odds of being prescribed an
opioid than naive patients (Lin et al., 2019). Moreover, if the
primary care physician was trained in complementary medicine,
he/she was significantly less likely to prescribe opioids (Rodondi
et al., 2019).
Additionally, opioid use was greater in patients with a pain-
related disability (Azevedo et al., 2013) and in those with more CP
conditions (Romanelli et al., 2017; Shmagel et al., 2018).
However, patients with a higher score on the Charlson
Comorbidity Index (2–3 vs. 0) had lower odds of receiving an
opioid (Romanelli et al., 2017) (Table 2).
Race was related to the use of opioids in two studies, which
showed that non-white patients (Larochelle et al., 2015) and
FIGURE 3 | Publication bias. Funnel plots of the subgroups B, D and E of the meta-analyses.
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Asian patients (Romanelli et al., 2017) were less likely to receive
opioids than non-Hispanic white patients (Table 2).
Results of the Meta-Analysis
The characteristics and results of the meta-analysis
(heterogeneity tests, estimated prevalences with 95% CI,
relative weights and tests for publication bias) of the
studies included in each of the six subgroups are shown in
Table 3, and the results of the logit transformations are
shown in Figure 2.
As shown in Table 3, we found heterogeneity within the
groups, demonstrating a marked variability among the
estimates (I2 > 77, p < 0.05, in all cases). Therefore, the model
used for the estimations of the summarized prevalence and logit
transformation was the random effects model.
Among the results obtained, it is noteworthy that in the
general population, the prevalence of long-term opioid use
among patients with general CNCP was 2.3% (95% CI:
1.5–3.6%), the prevalence of short-term opioid use was 8.1%
(95% CI: 5.6–11.6%), and the prevalence in CLBP was 5.8% (95%
CI: 0.5–45.5%). The prevalence among patients from health
registries or medical surveys was 41% (95% CI: 23.3–61.3%) in
patients with general CNCP. The prevalence in patients with
musculoskeletal conditions was 20.5% (95% CI: 12.9–30.9%) and
24.5% in patients with fibromyalgia (95% CI: 22.9–26.2%)
(Table 3).
Regarding the results obtained with the logit transformations,
negative summary measures were obtained in all the groups,
ranging from −3.745 in subgroup A, comprising subjects
receiving long-term opioid treatment for general CNCP from
general population surveys, to −0.365 in subgroup D, patients
receiving opioids for general CNCP from health records or
medical surveys (Figure 2).
Figure 3 shows the funnel plot for the meta-analysis of
subgroups B, D and E, suggesting no evidence of publication
bias. Neither Egger’s test nor Begg’s test were statistically
significant for the publication bias (Table 3).
Finally, Figure 4 shows the result of the sensitivity analysis for
subgroups B, D and E, indicating in the three cases that none of
the studies included would substantially change the overall result
of the summarized logit transformation if the studies were
eliminated from the meta-analysis. This finding indicates that
the results are robust, since none of the studies exerted a great
influence on the final result.
FIGURE 4 | Influence graphics for sensibility analysis of the subgroups B, D and E of the meta-analyses.
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DISCUSSION
This study analyzes the information published about the
prevalence of the use of opioids in patients with CNCP and
examines the factors associated with their use.
The results reveal that there were differences in the prevalence
of the use of these drugs depending on the length of the treatment
(2.3% in long duration or 8.1% in occasional use) (Fredheim et al.,
2014; Birke et al., 2016). It was also observed that when the
information derives from health registries, the prevalence is much
higher than in the general population, and more variable
depending on the chronic pain condition.
The lower prevalence found in patients with longer treatments
seems reasonable if we take into account, on the one hand, the
prescribers’ concern about the risk of addiction and the improper
use of these drugs by some patients (Allen et al., 2013) and, on the
other hand, the treatment dropout, possibly due to the appearance
of analgesic tolerance, induced hyperalgesia, side effects frequently
associated with these drugs, and insufficient pain relief (Kalso et al.,
2004; Noble et al., 2008; Sehgal et al., 2013). In this line, a recent
systematic review about opioids for CNCP concludes that the
benefits of opioids for pain and functioning are similar to non-
opioid alternatives. Opioid use was associated with small
improvements in pain and physical functioning, and increased
risk of vomiting compared with placebo (Busse et al., 2018).
The higher prevalence in the studies based on health registries
could be explained because these patients are usually treated in
specialized pain units, especially those patients with complex
types of pain conditions who do not respond to conventional
treatment and require special drugs, such as opioids (Henderson
et al., 2013; Pérez et al., 2013; De Sola et al., 2020). Furthermore, a
lack of healthcare providers offering effective treatment
alternatives is likely to have an impact on other treatment
choices (White et al., 2019). Another possible reason is the
difficulty in opioid deprescribing when patients have poor
function and unremitting pain or aberrant behavior and
misuse, since tapering is a complex process with little current
guidance available (White et al., 2019).
Regarding the specific pathologies, the prevalence in patients
with musculoskeletal conditions was 20.5% and in patients with
fibromyalgia 24.5% (Luo et al., 2004; Romanelli et al., 2017).
Musculoskeletal conditions are one of the most common causes
of pain (Breivik et al., 2006; Pierce et al., 2019) and the use of
weak opioids was recommended to relieve pain and disability in
the short-term in these patients (Airaksinen et al., 2006).
However, recent studies have found that LTOT is associated
with unrelieved pain, greater functional impairment, and lower
return to work rates (Turner et al., 2016; Krebs et al., 2018). In
line with this, current treatment guidelines do not recommend
opioids for fibromyalgia management (Peng et al., 2015),
possibly because opioids are unable to target the
pathophysiological processes involved in this central
sensitization syndrome (Menzies et al., 2017). Our findings
suggest that, despite a lack of scientific support of opioid
treatment in people with fibromyalgia and for
musculoskeletal conditions, clinicians are nevertheless
prescribing them for symptom management in these patients.
In the analysis of the factors associated with the use of opioids,
younger individuals showed greater use. One explanation could
be that opioids are not always recommended for the elderly
population due to a higher probability of liver or kidney
dysfunction, greater risk of respiratory depression, drug
interactions, organ dysfunction, co-morbidity and side effects,
such as constipation, drowsiness or sedation, which can have
more serious consequences in this population (Romanelli et al.,
2017). In addition, it has been shown that medical personnel
sometimes underestimate pain in the elderly, which leads to a
lower prescription of opioids in these patients (Raymond and
John, 2002; Seers et al., 2018).
Regarding race, different studies have shown that the pain
experience is different according to the ethnic group. This finding
has been attributed to different responses to painful stimuli and the
different coping strategies for managing pain between groups
(Campbell and Edwards, 2012; Larochelle et al., 2015; Ringwalt
et al., 2015; Romanelli et al., 2017). Additionally, according to
Anderson et al. (2009), there are other factors that could influence
these differences, such as selective care and differences in the
process of evaluation and allocation of treatment according to
the ethnic group of the patient.
Another factor to consider is the type of care received by the
patient. The type of medical insurance can influence the manner
of approaching the pain and consequently determine the use of
opioids. Patients with private insurance have been reported to
obtain better results than patients with public coverage
(Meineche-Schmidt et al., 2012) since, in addition to the fact
that the care is more immediate, a multidisciplinary approach is
more common and produces better results, decreasing the use of
analgesic treatment (Becker et al., 2000). In this vein, Rodondi
et al. (2019) highlighted that the training of the physician in
complementary medicine also results in the prescription of less
opioid treatments, since being specialized in integrative and
complementary medicine could help physicians to inform and
guide patients about the most effective treatment options, their
potential interactions with conventional therapies, and their side
effects.
Finally, it would be reasonable to think that in those studies
where the prevalence of CP is higher, the use of opioids would also
be greater (Barnett et al., 2012). However, when we compare the
results from different countries, this hypothesis is not confirmed, as
the factors that may be important are the method of data collection
and the characteristics of the population included in the studies
(Miller et al., 2017; Steingrímsdóttir et al., 2017). Likewise, the
cultural perceptions of pain could help us to understand the
differences in the prevalence of opioid use, the perception of
opioid use, the widespread marketing campaign for opioids, and
the regulations controlling the prescription of opioids (Severino
et al., 2018). Most of the studies included in this review were
performed in the US and Western Europe, where there are
significant differences in healthcare systems and healthcare
regulatory oversight, the financial incentive behind the treatment
of pain, and restrictions on the length of validity for these drugs,
among others (Meyer et al., 2020).
Some limitations of this review should be noted. It is worth
mentioning that three of the subgroups in the meta-analysis
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included only two studies. The minimum number of studies to
include in a meta-analysis has been discussed previously in the
literature, without clear agreement (Cooper et al., 2009;
Valentine et al., 2010; Pigott, 2012). Some researchers
consider that a minimum of five studies are desirable, or even
required. Others argue that, as long as the studies meet the
quality criteria and statistical requirements, the meta-analysis
can be carried out, as it is just a statistical combination of the
results. The number of studies in the literature on a topic is out
of our control, and the lack of studies on these topics (in our
case, studies carried out in the general population focused on
the prevalence of the long-term use of opioids; in the general
population focused on the prevalence of the use of opioids in
CLBP; and from health records or medical surveys focused on
the use of opioids in fibromyalgia) is itself a relevant result, and
it shows the need for further research on the topics. Of course,
the number of studies has a direct impact on the statistical
power and precision, but if those few studies are relevant and
their quality is high, we believe that it is worth drawing
conclusions from them. In this vein, Pigott (2012) argued
that the quick answer for the minimum number of studies
is two, but recommend computing the statistical power a priori
“using assumptions about the size of an important effect in a
given context, and the typical sample sizes used in a given
field.” Finally, Valentine et al. (2010) state that a meta-analysis
is always the best option to synthesize information (even if we
have few studies) as other alternatives “are likely to be based on
less defensible assumptions and on less transparent processes.”
Consequently, we decided to perform these three meta-
analyses which, however, need to be interpreted with
caution, given the limited statistical power.
In order to strengthen our findings, we attempted to limit the
impact of the clinical andmethodological heterogeneity, classifying
the studies into subgroups with similar characteristics. However,
the tests for statistical heterogeneity among the studies included in
the meta-analyses still demonstrated substantial variability
between them (I2 > 77, p < 0.05). A stratified analysis grouped
by the different nationalities of the patients or by the different
definitions of the prevalence of use of opioids in each study could
have been another potential way of classification based on the
importance of cultural aspects, healthcare systems, and healthcare
regulations in opioid use. However, the few studies with this
information available, and the marked heterogeneity within
the groups made another way to stratify them impossible. Also,
the differences in sociodemographic structure, socioeconomic
level and the duration of pain could contribute to the
differences between the study populations. However, without
access to individual patient data, it was not possible to control
these factors.
Another limitation of our review was the risk of bias in the
studies. Although 22 out of the 25 studies fulfilled at least seven
items of the checklist, only 12 fulfilled the nine items of the
Critical Appraisal Checklist for Studies Reporting Prevalence
Data, and just over half of the 25 studies included were not
primarily designed to produce prevalence data (Table 2). This
was reflected in the variability of reporting of important
variables. For example, population denominators and
response rates were not always identifiable and there were
occasional numerical discrepancies between the data
presented in the study abstract, main text, and results tables.
Despite the fact that some of the studies could have a potential
bias, the flaws are not sufficient to invalidate the results since
they satisfied other criteria in the assessment of the risk of bias
and provided important information in line with the objectives
of this review.
Despite extensive database searches, it is possible that some
references from the gray literature were missed. Furthermore,
language is one of the methodological limitations. All the studies
were in English, conducted in predominantly Western settings,
making generalizability to other parts of the world difficult. As a
strength of the study, we would like to highlight its novelty since,
to the best of our knowledge, no systematic review and meta-
analysis of the prevalence of the therapeutic use of opioids has
been published previously.
CONCLUSION
This study shows that the prevalence of opioid use among
patients with CNCP was higher in clinical studies based on
health registries and in subjects with short or occasional use
compared to those with long term use. Men, younger people,
more CP conditions, and patients without insurance or with
noncommercial insurance were most related to opioid use. In
contrast, non-white and Asian patients, and those treated by a
physician trained in complementary medicine were less likely
to use opioids.
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